Castle Biosciences CSTL Business Segments — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's business segments — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's business segments — D&A?
- Castle Biosciences (CSTL) reported business segments — D&A of $3.93M in Q1 2026.
- How has Castle Biosciences's business segments — D&A changed year-over-year?
- Castle Biosciences's business segments — D&A decreased by 86.8% year-over-year, from $29.76M to $3.93M.
- What is the long-term trend for Castle Biosciences's business segments — D&A?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — D&A has grown at a 57.0% compound annual growth rate (CAGR), from $10.54M to $40.77M.
- What does business segments — D&A mean?
- This represents the non-cash expense allocated to the reportable segment for the systematic reduction in the value of tangible and intangible assets over their useful lives. It reflects the capital intensity of the segment's operations and the ongoing investment required to maintain its diagnostic infrastructure.